Stifel Financial
AUPH icon

Stifel Financial’s Aurinia Pharmaceuticals AUPH Stock Holding History

Stifel Financial’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.73M Buy
168,774
+930
+0.6% +$14.8K ﹤0.01% 1832
2026
Q2 		$2.85M Buy
167,844
+2,443
+1% +$39K ﹤0.01% 1813
2026
Q1 		$2.45M Buy
+165,401
New +$2.42M ﹤0.01% 1812
2024
Q3 		– Sell
-17,064
Closed -$97.4K – 3372
2024
Q2 		$97.4K Sell
17,064
-13,204
-44% -$69.5K ﹤0.01% 3217
2024
Q1 		$152K Sell
30,268
-324,455
-91% -$2.2M ﹤0.01% 3133
2023
Q4 		$3.19M Sell
354,723
-391
-0.1% -$3.22K ﹤0.01% 1359
2023
Q3 		$2.76M Sell
355,114
-10,907
-3% -$107K ﹤0.01% 1381
2023
Q2 		$3.54M Buy
366,021
+13,975
+4% +$145K ﹤0.01% 1254
2023
Q1 		$3.86M Buy
352,046
+27,463
+8% +$242K 0.01% 1170
2022
Q4 		$1.4M Sell
324,583
-643,348
-66% -$3.73M ﹤0.01% 1768
2022
Q3 		$7.28M Sell
967,931
-73,606
-7% -$637K 0.01% 764
2022
Q2 		$10.5M Sell
1,041,537
-375,416
-26% -$4.2M 0.02% 639
2022
Q1 		$17.5M Buy
1,416,953
+682,793
+93% +$10.6M 0.02% 543
2021
Q4 		$16.8M Buy
734,160
+54,290
+8% +$1.29M 0.02% 555
2021
Q3 		$15M Buy
679,870
+177,655
+35% +$2.82M 0.02% 570
2021
Q2 		$6.51M Buy
502,215
+104,206
+26% +$1.33M 0.01% 884
2021
Q1 		$5.17M Buy
398,009
+96,943
+32% +$1.41M 0.01% 944
2020
Q4 		$4.16M Buy
301,066
+152,638
+103% +$2.22M 0.01% 963
2020
Q3 		$2.19M Buy
148,428
+23,110
+18% +$335K ﹤0.01% 1165
2020
Q2 		$2.04M Buy
125,318
+63,476
+103% +$1.02M ﹤0.01% 1143
2020
Q1 		$894K Buy
61,842
+12,258
+25% +$216K ﹤0.01% 1506
2019
Q4 		$1M Buy
49,584
+6,573
+15% +$60.5K ﹤0.01% 1832
2019
Q3 		$231K Buy
43,011
+1,902
+5% +$11.5K ﹤0.01% 2576
2019
Q2 		$271K Sell
41,109
-5,411
-12% -$34.5K ﹤0.01% 2550
2019
Q1 		$303K Buy
46,520
+3,520
+8% +$23.4K ﹤0.01% 2351
2018
Q4 		$295K Sell
43,000
-2,196
-5% -$12.7K ﹤0.01% 2241
2018
Q3 		$300K Buy
45,196
+3,378
+8% +$18.9K ﹤0.01% 2360
2018
Q2 		$236K Buy
41,818
+20,100
+93% +$112K ﹤0.01% 2446
2018
Q1 		$113K Buy
21,718
+10,772
+98% +$57.6K ﹤0.01% 2555
2017
Q4 		$49K Buy
+10,946
New +$60.8K ﹤0.01% 2591

Other funds holding AUPH

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Jupiter Asset Management
Jupiter Asset Management London, United Kingdom $21.4B AUM 19.74% 1-Year Est. Return
O'Shaughnessy Asset Management
O'Shaughnessy Asset Management Stamford, Connecticut $23.6B AUM 34.05% 1-Year Est. Return
Hillsdale Investment Management
Hillsdale Investment Management Toronto, Ontario, Canada $4.42B AUM 54.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

Stifel Financial's AUPH Position: Q3 2026 in Review

Stifel Financial increased its Aurinia Pharmaceuticals (AUPH) stake by 0.55% in Q3 2026, buying an estimated $14.8K and bringing the position to 168,774 shares worth $2.73M. The position accounts for ﹤0.01% of the portfolio, ranked #1832.

Stifel Financial first reported a position in AUPH in Q4 2017 and has held it in 30 quarters since. The position peaked at $17.5M in Q1 2022. 170 funds tracked by Wall St. Rank hold AUPH as of Q3 2026.

  • Stifel Financial held 168,774 shares of Aurinia Pharmaceuticals worth $2.73M as of Q3 2026.
  • Stifel Financial bought 930 Aurinia Pharmaceuticals shares in Q3 2026, an estimated $14.8K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Stifel Financial's portfolio in Q3 2026, its #1832 holding.
  • Stifel Financial first reported a position in Aurinia Pharmaceuticals in Q4 2017 and has held it in 30 quarters since.
  • Stifel Financial's Aurinia Pharmaceuticals position peaked at $17.5M in Q1 2022.
  • 170 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2026.

Based on Stifel Financial's 13F filing for Q3 2026, filed 12 Nov 2026.